NewcelX Ltd. (NCEL)
NASDAQ: NCEL · Real-Time Price · USD
2.740
-0.030 (-1.08%)
At close: Mar 9, 2026, 4:00 PM EDT
2.740
0.00 (0.00%)
After-hours: Mar 9, 2026, 5:22 PM EDT
Company Description
NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.
NewcelX Ltd.
| Country | Switzerland |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Ronen Twito |
Contact Details
Address: The Circle 6 Zurich, 8058 Switzerland | |
| Phone | 41 44 512 21 50 |
| Website | newcelx.com |
Stock Details
| Ticker Symbol | NCEL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | ILS |
| CIK Code | 0001783036 |
| CUSIP Number | H5835A109 |
| ISIN Number | CH1442297896 |
Key Executives
| Name | Position |
|---|---|
| Ronen Twito CPA | Chief Executive Officer and Executive Chairman |
| Prof. Michel Revel M.D., Ph.D. | Co-Founder, Chief Scientist, Head of the Scientific Advisory Board and Director |
| Yossi Ben-Yossef | Honorary President and Strategic Consultant |
| Omri Hagai | Chief Financial Officer |
| Alexander C. Zwyer M.B.A. | Chief Business Officer and Executive Director |
| Dr. Eric Konofal M.D., Ph.D. | Head of Doxa Program |
| Prof. Ariel Revel M.D. | Director of Medical Affairs |